Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    15948116 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Dasatinib

Indicates status has not been verified in more than two years